Engineered immune cells take aim at two cancer targets in hard-to-treat bile duct cancers
NCT ID NCT07641036
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new therapy called EB-HC01, which uses specially engineered natural killer (NK) immune cells to attack cancer cells that have two specific markers (HER2 and CEACAM5). The trial enrolls adults with advanced bile duct or gallbladder cancers that have worsened after standard chemotherapy. Participants receive the NK cells along with a short course of chemotherapy to prepare the immune system. The study first checks safety and dosing, then looks at whether the therapy shrinks tumors and how long any benefit lasts.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
EB-HC01 (dual-target HER2/CEACAM5 chimeric antigen receptor natural killer cells)
What this could lead to
If successful, this could offer a new treatment option for people with advanced biliary tract cancers that have not responded to standard chemotherapy.
What could go wrong
This is an early-phase trial with only 30 participants, so results may not apply broadly. The therapy involves lymphodepletion chemotherapy and carries risks of side effects, including immune reactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHOLANGIOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University Shenzhen Hospital
RECRUITINGShenzhen, Guangdong, 518036, China
Contact Phone: •••-•••-•••• Email: •••••@•••••